• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    What Bonesupport Holding Stock Strong Quarterly Earnings Means For Shareholders

    Simply Wall St·10/31/2026 14:42:20
    语音播报
    • Bonesupport Holding reported third quarter 2026 sales of SEK 408.83 million and net income of SEK 92.36 million, with basic EPS from continuing operations of SEK 1.41, alongside completion of a SEK 142.6 million share buyback covering 641,320 shares or 0.97% of the company.
    • The combination of higher year to date sales of SEK 1,088.57 million, improved nine month net income of SEK 227.62 million, and an executed buyback program indicates a business generating enough cash and earnings to both fund operations and actively manage its capital structure.
    • The next step is to examine how Bonesupport Holding's stronger third quarter earnings profile could reshape the investment narrative that analysts previously outlined.
    Spot other businesses pairing solid earnings with active buybacks by scanning our hand picked 199 high quality undervalued stocks for potential ideas alongside Bonesupport Holding.

    Bonesupport Holding Investment Narrative Recap

    To own Bonesupport Holding, you need to believe CERAMENT products can keep gaining traction in U.S. and European orthopedic infection cases while hospitals work through periodic go/stop/go purchasing patterns. The latest third quarter and nine month figures show the business generating earnings and cash that support that thesis without radically changing the near term story.

    The key short term swing factor still sits in how smoothly U.S. hospitals embed CERAMENT G into protocols and whether clinical confidence stays intact despite scrutiny of earlier elution data. Tariffs and potential gross margin pressure remain the main operational risk, and the October numbers do not remove that concern.

    The most relevant update is the October third quarter report itself, which puts sales at SEK 408.83 million and net income at SEK 92.36 million, with basic EPS from continuing operations of SEK 1.41. For nine months, Bonesupport Holding reported SEK 1,088.57 million in sales and SEK 227.62 million in net income, giving more scale behind CERAMENT adoption.

    Those earnings arrive alongside the completed SEK 142.6 million share buyback covering 0.97% of the business, which includes SEK 59.7 million spent on 268,000 shares between July and October. Together, the stronger profit base and smaller share count tighten the focus on execution risks around hospital ordering patterns, tariff effects and the timing of any CERAMENT V approval.

    Bonesupport Holding's analyst narrative points to SEK 3.1b revenue and SEK 989.4 million earnings by 2029, based on the provided forecast of annual revenue growth of 30.1% and an earnings increase of about 3.6x from SEK 271.8 million today.

    Uncover how Bonesupport Holding's fair value indicates a 15% potential upside to its current price before the market closes that gap.

    OM:BONEX 1-Year Stock Price Chart
    OM:BONEX 1-Year Stock Price Chart

    Exploring Other Perspectives

    For Bonesupport Holding, the alternate story hinges on the buyback as a catalyst. The most optimistic analysts were already pencilling in SEK 2.8b of revenue and SEK 793.6 million of earnings by 2029 before this repurchase was completed. That more upbeat camp may now reassess the capital return and revise their narrative further, while others stay cautious.

    Explore 3 other Bonesupport Holding fair value estimates, including one that suggests as much as 32% upside from the current price.

    Decide For Yourself

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking for more investment ideas beyond Bonesupport Holding?

    If the Bonesupport Holding story has sharpened your thinking, use that momentum to scan a wider field of opportunities that fit different risk and income preferences.